Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05581979
Other study ID # PSMA 01
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 26, 2022
Est. completion date June 2024

Study information

Verified date February 2024
Source National Cancer Centre, Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objectives of this pilot feasibility study, which is on the use of 68-Ga PSMA PET imaging of salivary gland tumours, are - to determine the proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer; and - to determine if in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers. The hypotheses of this study are that there is high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers; and that in vitro PSMA expression correlates to PSMA-ligand uptake on Ga-68 PSMA imaging.


Description:

The potential participant will be screened and confirmed for eligibility by the appropriate study-team member. A signed IRB approved informed consent will be obtained prior to conducting any study-related procedures. On the scheduled visit date for the study, - An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes. - PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously. - A PET scan will be done around 60 minutes after the injection of the 68-Ga PSMA imaging agent. - During imaging, the participant will be asked to lie still and may be asked to hold his/her breath for a few seconds. - Imaging will be performed using a PET/CT, which will take 30 to 40 minutes to complete. Imaging of the body from vertex to mid thigh or feet will be obtained. - After the completion of the scan, the plug will be removed. A Final Study Visit will take place on that one scheduled day. The participant will not need to visit the doctor's office during the course of the study outside of their usual scheduled doctor's follow up appointments.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4
Est. completion date June 2024
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 99 Years
Eligibility Inclusion Criteria: - Locally advanced, metastatic or locally recurrent salivary gland cancers OR rare cancers (Examples of rare cancers: thyroid ca, cholangio ca, pancreatic ca, gall bladder ca, sarcoma) - Sample of biopsied tissue available for analysis - Histologically confirmed diagnoses - Above 21 years of age - Able to provide informed consent Exclusion Criteria: - Those who do not meet above inclusion criteria - Diagnosis of haematological malignancies - Patients with more than one cancer diagnosis - Contraindication to 68Ga-PSMA PET/CT - E.g.: pregnant patients, breast feeding patients, renal impairment, liver impairment, allergy to components of the test - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule - Ongoing participation in any other clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
68-Ga PSMA PET scan
On the scheduled visit date for the study, An intravenous cannula (plug) will be inserted in a vein in the participant's arm, through which the 68-Ga PSMA radiotracer for the scan will be injected. The infusion will take about 1-2 minutes. PET imaging will be performed with a dedicated PET/CT scanner. 2.5-6.0 mCi (depending on weight of the patient) of PSMA radiotracer will be injected intravenously.

Locations

Country Name City State
Singapore National Cancer Centre Singapore Singapore

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Centre, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of patients with high PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer. The proportion of patients with PSMA-ligand uptake greater than liver uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancer. Through study completion, to June 2024.
Secondary Correlation between in vitro PSMA expression and PSMA-ligand uptake on Ga-68 PSMA imaging in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers. Correlation between the value of IHC PSMA expression and the PSMA PET SUVmax in locally advanced, recurrent or metastatic salivary gland cancers and other rare cancers. Through study completion, to June 2024.
See also
  Status Clinical Trial Phase
Completed NCT04970875 - Partial Modified Blair Incision on Benign Tumor Parotidectomy Scar's Characteristics
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Recruiting NCT06047236 - Immune Biomarker Study for Salivary Gland Carcinoma
Active, not recruiting NCT04249947 - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Phase 1
Completed NCT06034782 - Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.
Recruiting NCT04452162 - Physiologic MR Imaging of Salivary Gland Tumors N/A